Oddo BHF - BioNTech SE (BNTX) BioNTech SE : RD Day focused on oncology

Report

Oddo BHF

Damien Choplain ...

Martial Descoutures

BioNTech SE : R&D Day focused on oncology

>Three complementary approaches for five flagship molecules - - At yesterday's R&D day, BioNTech focused on its oncology portfolio structured around three complementary and potentially synergistic approaches: immunomodulators, mRNA vaccines and targeted therapy. On the product side, the company highlighted five flagship molecules: 1/ BNT327 (PDL1x VEGF bispecific), 2/ BNT122 autogenous cevumeran (individualised mRNA vaccine), 3/ FixVac (Off-the-shelf mRNA vaccin...

15/11/2024 1 EN

Underlying

BioNTech SE

See profile

US09075V1026 NASDAQ Stock Market Germany

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Damien Choplain

Martial Descoutures

Other Reports on these Companies

Oddo BHF

BioNTech SE : R&D Day tourné vers l’oncologie

>Trois approches complémentaires pour 5 actifs flagships - Lors du R&D day qui s’est tenu hier, BioNTech a fait un focus sur son portefeuille en oncologie structuré autour de trois approches complémentaires et potentiellement synergiques : immunomodulateurs, vaccins à ARNm et thérapie ciblée. Coté produits, la société a mis en avant 5 molécules flagships : 1/ BNT327 (bispécifique PDL1x VEGF), 2/ BNT122 autogene cevumeran (Vaccin à ARNm personnalisé), 3/ FixVac (Vacc...

3h / 6m 3h / 6m 1 FR

GlobeNewsWire

BioNTech kündigt Übernahme von Biotheus zur beschleunigten Umsetzung der Onkologie-Strategie an

BioNTech kündigt Übernahme von Biotheus zur beschleunigten Umsetzung der Onkologie-Strategie an Übernahme soll globale Umsetzung von BioNTechs Onkologie-Strategie unterstützen und die weltweiten Rechte an BNT327/PM8002 sichern; der Kandidat ist ein PD-L1 x VEGF-A bispezifischer Antikörper, der das Potenzial hat, derzeitige Standardtherapien mit Checkpoint-Inhibitoren bei soliden Tumoren zu ersetzen.Die geplante Übernahme von Biotheus hat das Ziel, BioNTechs Fähigkeiten zur Entwicklung, Herstellung und Kommerzialisierung von bispezifischen Antikörperkandidaten der nächsten Generation sowie i...

November 13, 2024 November 13, 2024 1 EN

Reply Spa : Q3 2024 earnings beat expectations. Confidence on Q4. Reply continues to largely outperform peers

>Q3 organic growth of 8.4% (vs 7.7%e). Solid profitability - Yesterday during trading Reply published its Q3 2024 results followed by a conference call. Revenue was € 552.6m, up 8.5% of which 8.4% organic, a shade above forecasts (vs 7.7%e) and representing an acceleration vs Q2 (+7.7%). This performance was primarily driven by solid growth in financial services (Q3: 10.9% y-o-y vs Q2: 6.2%, Q1: 3.3%) and retail & CPG (Q3: 7.6% vs Q2: 2.8%, Q1: -0.8%). This helps to o...

2h / 28m 2h / 28m 1 EN

Louis Boujard ... (+3)

Louis Boujard
CFA
Philippe Ourpatian

Acciona Energia : Trading statement is in line and EBITDA guidance confirmed

>9M 2024 in line, driven by hydro and wind in Spain, but penalised by prices - Acciona Energia has released its trading statement for 9M 2024. Installed capacity was 14.3 GW vs 12.9 GW a year earlier. Consolidated capacity increased to 12.7 GW vs 11.6 GW, up 10.4%. Capacity under construction was 1.3 GW (vs 1.6 GW at 9M 2023), i.e. a slight decline, via projects largely located in Australia (430 MW), India (413 MW), Canada (171 MW) and the Philippines (101 MW). Consol...

2h / 32m 2h / 32m 1 EN

Baptiste Lebacq

Baptiste Lebacq

Vallourec : EBITDA 11%< expectations // Faster deleveraging // Return of dividends

>Q3 2024 EBITDA 11% < expectations but faster-than-expected deleveraging - Q3 2024 EBITDA came to € 168m, down 22% vs Q2 2024 and below our estimate of € 189m (consensus € 192m). The EBITDA margin was 19%. Tubes EBITDA fell from € 193m in Q3 2023 to € 162m in Q3 2024 due to the fall in profitability in North America. Mine & Forest EBITDA was € 22m in Q3 2024, versus € 39m in Q3 2023, reflecting the decrease in iron ore production sold and lower selling price...

2h / 34m 2h / 34m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BioNTech SE : R&D Day focused on oncology

BioNTech SE : R&D Day tourné vers l’oncologie

BioNTech kündigt Übernahme von Biotheus zur beschleunigten Umsetzung der Onkologie-Strategie an

Reply Spa : Q3 2024 earnings beat expectations. Confidence on Q4. Reply continues to largely outperform peers

Acciona Energia : Trading statement is in line and EBITDA guidance confirmed

Vallourec : EBITDA 11%< expectations // Faster deleveraging // Return of dividends

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe